Arrowhead Pharmaceuticals (ARWR) said Monday it dosed the first patients in a phase 1/2a clinical trial of ARO-INHBE, the company's investigational therapy to counter obesity.
The study will treat patients with ARO-INHBE as monotherapy in part 1 and in combination with tirzepatide in part 2.
The company also recently filed for regulatory clearance to launch a clinical trial of its second obesity candidate, ARO-ALK7.
Shares of the company were up more than 2.5% in Monday's premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。